

South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2024 - September 30, 2025

Department	Project Number	Project Title	Principal Investigator	Source of Funding	24-25 Receipts
Internal Medicine	63891	CorEvitas Inflammatory Bowel Disease (IBD) Drug Safety and Effectiveness Registry (Corrona IBD-600 Registry)	Dr Sonnier, W	CorEvitas	38,890.00
	63949	NN7533-4470- ASCENT A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine-Tetrahydouridine (NDec) in Patients with Sickle Cell Disease (NN7533-4470 - ASCENT)	Dr Hogue, A	Novo Nordisk	3,000.00
	63971	ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction	Dr Malozzi, C	Novo Nordisk	8,700.00
	63972	A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)	Dr Fusco, D	AiCuris Anti-Infection Cures AG	59,565.50
	Total Internal Medicine				110,155.50
Mitchell Cancer Institute	63937	A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy (LP-CT-PALO 202101)	Dr Butler, T	Xiamen LP Pharmaceuticals	17,859.92
	63953	A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia (BeiGene - BGB-3111-402)	Dr Alkharabsheh, O	BeiGene, Ltd.	2,366.00

**South Alabama Medical Science Foundation**  
**Cash Receipts (For Projects Over \$2,000)**  
**October 1, 2024 - September 30, 2025**

Department	Project Number	Project Title	Principal Investigator	Source of Funding	24-25 Receipts
	63960	A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011-0014)	Dr Alkharabsheh, O	Merck Sharp & Dohme LLC	98,392.80
	63965	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)	Dr Alkharabsheh, O	Bristol Myers Celgene Corp	9,200.00
	63966	A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator's Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2	Dr Abdalla, A	AstraZeneca Pharmaceuticals LP	31,978.16
	63970	A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)	Dr Pierce, J	Merck Sharp & Dohme LLC	16,500.00
	63974	An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers	Dr Abdalla, A	AstraZeneca Pharmaceuticals LP	9,882.00
Total Mitchell Cancer Institute					<b>186,178.88</b>

South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2024 - September 30, 2025

Department	Project Number	Project Title	Principal Investigator	Source of Funding	24-25 Receipts
Neurology	63867	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (Xenon XPF-008-201)	Dr Naritoku, D	Xenon Pharmaceuticals, Inc.	5,385.21
	63898	Success in Comaneci-assist Coils Embolization Surveillance Study	Dr Sugg, R	Rapid Medical Ltd	3,000.00
	63940	A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures (Xenon XPF-010-301)	Dr Naritoku, D	Xenon Pharmaceuticals, Inc.	7,857.94
	63950	A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy	Dr Naritoku, D	Xenon Pharmaceuticals, Inc.	10,700.00
	63975	A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus(Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis	Dr Kilgo, W	Amgen, Inc	11,077.00
				Total Neurology	38,020.15

South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2024 - September 30, 2025

Department	Project Number	Project Title	Principal Investigator	Source of Funding	24-25 Receipts
Neurosurgery					
	63952	PAULA - Pelvic fixation and fusion during multilevel spinal surgery (SI-BONE - PAULA)	Dr Menger, R	SI-BONE, Inc.	11,795.00
				Total Neurosurgery	11,795.00
OB-GYN					
	63979	A PHASE 3 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING SUBSEQUENT PREGNANCIES AND PERSISTENCE OF IMMUNITY OF A SINGLE DOSE OF A BIVALENT RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE	Dr Roth, T	Pfizer	13,150.00
				Total OB-GYN	13,150.00
Pediatrics					
	63913	An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickel Cell Disease Who Have Participated in an Inclacumab Clinical Trial (GBT2104-133)	Dr Marri, P	Global Blood Therapeutics, Inc.	4,573.60
	63926	A Phase 2, Double-Blind, 12-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease (TAK-390MR_204)	Dr Gremse, D	Takeda Development Ctr Americas, Inc.	65,534.89
	63927	A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE (TAK-390MR_205)	Dr Gremse, D	Takeda Development Ctr Americas, Inc.	44,233.90

South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2024 - September 30, 2025

Department	Project Number	Project Title	Principal Investigator	Source of Funding	24-25 Receipts
	63931	Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels (QOL - SSDXP-13)	Dr Gremse, D	QOL Medical, LLC	4,782.50
	63932	A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years (FIPCUS CLENPIQ 000359)	Dr Gremse, D	Ferring Pharmaceuticals	80,765.77
	63973	HIBISCUS 2: A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease	Dr Imran, H	Novo Nordisk, Inc	13,700.00
	Total Pediatrics				213,590.66
	Trauma Center				
	63976	A Prospective Multicenter Single-arm Clinical Study Investigating Clinical Outcomes when Cohealyx™ is used for the Management of Full Thickness Wounds Post-surgical Excision (CTP011)	Dr Butts, C	AVITA Medical Americas, LLC	9,450.00
	Total Sickle Cell				9,450.00
Sickle Cell					
	63945	GBT 440-4R2 An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor) (GBT-440-4R2)	Dr Pack-Mabien, A	Global Blood Therapeutics, Inc.	20,191.90
Total Sickle Cell					20,191.90

*South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2024 - September 30, 2025*

Department	Project Number	Project Title	Principal Investigator	Source of Funding	24-25 Receipts
------------	-------------------	---------------	------------------------	-------------------	-------------------

South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2024 - September 30, 2025

Department	Project Number	Project Title	Principal Investigator	Source of Funding	24-25 Receipts
Surgery	63910	Research to further inform thinking about the role of LINX for Reflux Disease (Torax Rethink Reflux Registry - TRX_2018_01)	Dr Richards, W	Torax Medical/Ethicon Endo-Surgery	5,515.00
	63930	A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4 Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex®]) to Improve Survival in Patients with Traumatic Injury and Acute Major Bleeding (BE1116_3006)	Dr Butts, C	CSL Behring LLC	10,583.00
	63961	Randomized Study of the pdSTIM™ System (phrenic nerve to diaphragm STIMulation) in Failure to Wean Mechanically Ventilated Patients (ReInvigorate Study - CIP0002)	Dr Mbaka, M	Stimdia Medical, Inc.	3,861.00
	Total Surgery				19,959.00
Urology	63968	A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)	Dr Keel, C	Ferring Pharmaceuticals	3,500.00
	Total Urology				3,500.00
Total All Departments					625,991.09
Other Research Related Revenue					
	62648	Royalty On Sales of Antibody Products	Dr Scammell, J	LEINCO TECH BIO	3,390.50

South Alabama Medical Science Foundation  
Cash Receipts (For Projects Over \$2,000)  
October 1, 2024 - September 30, 2025

Department	Project Number	Project Title	Principal Investigator	Source of Funding	24-25 Receipts
				Total Other Research	3,390.50
				Total	629,381.59